AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.
CARDIOR
ExitCardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.
